Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Breast Neoplasms 114Ovarian Neoplasms 71Triple Negative Breast Neoplasms 57Fallopian Tube Neoplasms 43Endometrial Neoplasms 42Squamous Cell Carcinoma of Head and Neck 40Lung Neoplasms 40Neoplasm Metastasis 35Stomach Neoplasms 28Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 20Head and Neck Neoplasms 16Carcinoma 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Colorectal Neoplasms 13Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Melanoma 9Adenocarcinoma Of Esophagus 9Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Peritoneal Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

Cyclophosphamide 49fludarabine 36Dexamethasone 35venetoclax 29pembrolizumab 26Rituximab 21Lenalidomide 18pomalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 11carfilzomib 11Temozolomide 11Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Injections 9Azacitidine 9selinexor 8Vincristine 8Carboplatin 8Bortezomib 8obinutuzumab 7Immunotherapy, Adoptive 7Bevacizumab 7zanubrutinib 6ruxolitinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × Paclitaxel × 1 year × Clear all
NCT00864318 2026-04-14

TICE

Institut Claudius Regaud

Phase 2 Completed
101 enrolled

Neoplasms, Germ Cell and Embryonal, Recurrence

NCT07423078 2026-04-13

WOLF

University of Pittsburgh

Phase 2 Recruiting
87 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03315364 2026-04-01

OPTIMAL

Daehwa Pharmaceutical Co., Ltd.

Phase 2/3 Active not recruiting
549 enrolled
Breast

Breast Neoplasms, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

University of Pittsburgh

Phase 2 Recruiting
15 enrolled

Recurrence

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting
785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡